A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers

计划入组 32 人 · 首次发布于 2023 年 10 月 25 日

Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation

计划入组 200 人 · 首次发布于 2025 年 12 月 5 日

A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)

计划入组 66 人 · 首次发布于 2020 年 10 月 1 日

A3-APO

AP-31969（Acesion Pharma ApS）

AP1

Acrivon Therapeutics

United States

Cell2Cure ApS

Denmark

Thrombologic ApS

Denmark

Acrivon Therapeutics to Showcase AP3 Platform and Clinical Program Updates at Upcoming R&D Event

Acrivon Therapeutics Initiates Phase 1 Trial of WEE1/PKMYT1 Inhibitor ACR-2316 for Solid Tumors

Acrivon Therapeutics Grants Equity Awards to Employees Under Nasdaq Rule 5635(c)(4)